RT Journal Article
T1 Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort.
A1 Vazquez-Bourgon, Javier
A1 Mayoral-van Son, Jaqueline
A1 Gomez-Revuelta, Marcos
A1 Juncal-Ruiz, Maria
A1 Ortiz-Garcia de la Foz, Víctor
A1 Tordesillas-Gutierrez, Diana
A1 Ayesa-Arriola, Rosa
A1 Bioque, Miquel
A1 Crespo-Facorro, Benedicto
K1 Treatment discontinuation
K1 lipid metabolism
K1 medication-naïve
K1 second-generation antipsychotic
K1 weight gain
AB Patients with a first episode of psychosis (FEP) are at higher risk of gaining weight and presenting metabolic disturbances, partly related to antipsychotic exposure. Previous studies suggest that treatment discontinuation might have a positive impact on weight in schizophrenia. The aim of this study was to evaluate the effect of treatment discontinuation on weight and metabolic changes in a FEP cohort. A total of 209 FEP patients and 57 healthy controls were evaluated at study entry and prospectively at 10-year follow-up. Anthropometric measures and, clinical, metabolic, and sociodemographic data were collected. Patients discontinuing antipsychotic treatment presented a significantly lower increase in weight and better metabolic parameter results than those still on antipsychotic treatment at 10-year follow-up. Treatment discontinuation had a positive effect on the weight and metabolic changes observed in FEP patients; however, this effect was not sufficient to reaching a complete reversal to normal levels.
PB Oxford University Press
YR 2020
FD 2020-08-25
LK http://hdl.handle.net/10668/16148
UL http://hdl.handle.net/10668/16148
LA en
NO Vázquez-Bourgon J, Mayoral-van Son J, Gómez-Revuelta M, Juncal-Ruiz M, Ortiz-García de la Foz V, Tordesillas-Gutiérrez D, et al. Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort. Int J Neuropsychopharmacol. 2021 Jan 20;24(1):1-7.
NO The authors wish to thank all the PAFIP research team and all patients and family members who participated in the study.This work was supported by the Instituto de Salud Carlos III (grant nos. PI020499, PI050427, and PI060507) and the Valdecilla Insitute of Biomedical Research (grant no. NVAL17/24).
DS RISalud
RD Apr 12, 2025